A Secret Weapon For Nemifitide diTFA
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Most important demo targets were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymy